Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AlmirallSTU:E2Z +0.79%71 EV-to-EBITDA is 11.41 as of Sep. 15, 2026, which is 4% above its 10-year median of 11.00. GuruFocus rates STU:E2Z with a GF Score™ of 71/100 and a GF Value™ of €16.12 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 728 Drug Manufacturers companies, Almirall ranks better than 76.51% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Almirall's enterprise value is €2,220 Mil.
Almirall's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €195 Mil. Therefore, Almirall's EV-to-EBITDA for today is 11.41.
The historical rank and industry rank for Almirall's EV-to-EBITDA or its related term are showing as below:
STU:E2Z'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -20.03 Med: 11 Max: 79.87
Current: 6.82
During the past 13 years, the highest EV-to-EBITDA of Almirall was 79.87. The lowest was -20.03. And the median was 11.00.
STU:E2Z's EV-to-EBITDA is ranked better than 76.51% of 728
companies
in the Drug Manufacturers industry
Industry Median: 13.375
vs STU:E2Z: 6.82
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Almirall's share price for today is €10.24.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Almirall's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €0.329.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Almirall's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:E2Z vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Almirall's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Almirall EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Almirall's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Almirall's EV-to-EBITDA falls into.
Almirall's current Enterprise Value is €2,220 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Almirall's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €195 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Almirall (STU:E2Z) has a EV-to-EBITDA of 11.41 as of Sep. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Almirall. This is near median its historical median of 11.00. According to the industry distribution chart, Almirall ranks #171 out of 728 companies in the Drug Manufacturers industry, placing it in the top 23.5%.
Is Almirall's EV-to-EBITDA too high?
Almirall's current EV-to-EBITDA of 11.41 is near median its 10-year median of 11.00. The Drug Manufacturers industry median EV-to-EBITDA is 13.38. Almirall's value of 11.41 is 14.7% below this industry median. Based on the distribution chart, Almirall ranks #171 out of 728 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Almirall has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Almirall's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Almirall ranks #171 out of 728 companies for EV-to-EBITDA. This places Almirall in the top 24% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.38. Almirall's value of 11.41 is 14.7% below this benchmark. While the company's 10-year median is 11.00 vs. the industry median of 13.38, Almirall has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.38, based on 728 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Almirall's current EV-to-EBITDA of 11.41 is 14.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Almirall. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Almirall's current EV-to-EBITDA is 11.41, which is near median its own 10-year median of 11.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Almirall stock overvalued right now?
Based on GuruFocus' analysis, Almirall (STU:E2Z) is currently considered Significantly Undervalued. The stock's GF Value™ is €16.12, compared to a current price of €10.24 — trading 36.5% below its estimated fair value. The current EV-to-EBITDA is 11.41, which is near median its 10-year median of 11.00 and 14.7% below the Drug Manufacturers industry median of 13.38. Almirall's overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Almirall (STU:E2Z), the current EV-to-EBITDA is 11.41 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Almirall (STU:E2Z) Overvalued in 2026?
Based on GuruFocus' analysis, Almirall stock appears to be undervalued.
The current stock price of €10.24 is trading 36.5% below its estimated GF Value™ of €16.12.
GuruFocus considers Almirall to be Significantly Undervalued.
Key valuation signals for STU:E2Z:
EV-to-EBITDA: 11.41 (near median its 10-year median of 11.00)
GF Value™: €16.12 vs. price of €10.24 (36.5% below fair value)
Industry Position: 14.7% below the Drug Manufacturers median (#171 of 728)
No single metric tells the full story. See the STU:E2Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Almirall SA is a skin-health focused pharmaceutical company based in Barcelona and the parent company of a group engaged in the purchase, manufacture, storage, marketing, and mediation in the sale of pharmaceutical specialities and products, as well as related raw materials. The Group applies science to provide medical solutions focused on skin health diseases and partners with healthcare professionals, and its activities also include cosmetics; chemical, biotechnological and diagnostic products for human, veterinary, agrochemical and food use; instruments and accessories for the chemical, pharmaceutical and clinical industry; and research on active chemical and pharmaceutical ingredients and products.
71GF Score
Get the complete analysis for STU:E2Z
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:E2Z has been successfully added to your 
